Foreign companies believe they are unfairly being singled out for scrutiny in bribery and pricing investigations, the biggest European business group in China said Thursday.
The comments by officials of the European Chamber of Commerce in China follow announcements about fines imposed on dairy suppliers over pricing issues and an investigation into possibly bribery by employees of drug manufacturers GlaxoSmithKline and Sanofi.
"What I feel a little bit unfair, the foreign companies that are most serious about SOPs have been the most investigated and the most discriminated," said the president of the chamber's pharmaceutical working group, Bruno Gensberger. "To my knowledge, today no Chinese company has been investigated." Read more
